

## Special Issue

# Estimating Vaccines' Value and Impact

### Message from the Guest Editor

Estimating the value and public health impact of vaccines is critical to ensure evidence-based policy decision making in nearly all stages, from vaccine development to the introduction/implementation of vaccines in low-resource settings. To foster public health equity, as well as estimate value to local and national economies, concerted efforts are needed to increase the understanding of the full value of vaccination. Such value goes beyond direct disease prevention and can, for example, include impacts on the life course of vaccinated recipients, on the wider community, and on entire health systems. We are pleased to invite you to contribute with your research work to provide readers (e.g., member states, global policymakers, funding entities, and/or the vaccine R&D community) with insights on how the “full” value of vaccines can be assessed or was assessed by you. This can be carried out through concrete assessments that you undertook or by offering methodological advice that can help the growing community of researchers and implementers to inform as well as optimize responses to vaccine-preventable diseases.

### Guest Editor

Dr. Philipp Lambach

Department of Immunization, Vaccines and Biologicals (IVB), World Health Organization, 1211 Geneva, Switzerland

### Deadline for manuscript submissions

closed (30 June 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/169968](https://mdpi.com/si/169968)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).